2-169191425-A-C

Position:

• chr2-169191425-A-C

Variant summary

Our verdict is Benign. Variant got -12 ACMG points: 0P and 12B. BP4_Strong BA1

The NM_004525.3(LRP2):​c.9032+407T>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.716 in 152,116 control chromosomes in the GnomAD database, including 40,589 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.

• Frequency: Genomes: 𝑓 0.72 (40589 hom., cov: 32)
• Consequence: LRP2 NM_004525.3 intron
• Clinical Significance: Not reported in ClinVar
• Conservation: PhyloP100: -0.808

Genes affected

LRP2 (HGNC:6694): (LDL receptor related protein 2) The protein encoded by this gene, low density lipoprotein-related protein 2 (LRP2) or megalin, is a multi-ligand endocytic receptor that is expressed in many different tissues but primarily in absorptive epithilial tissues such as the kidney. This glycoprotein has a large amino-terminal extracellular domain, a single transmembrane domain, and a short carboxy-terminal cytoplasmic tail. The extracellular ligand-binding-domains bind diverse macromolecules including albumin, apolipoproteins B and E, and lipoprotein lipase. The LRP2 protein is critical for the reuptake of numerous ligands, including lipoproteins, sterols, vitamin-binding proteins, and hormones. This protein also has a role in cell-signaling; extracellular ligands include parathyroid horomones and the morphogen sonic hedgehog while cytosolic ligands include MAP kinase scaffold proteins and JNK interacting proteins. Recycling of this membrane receptor is regulated by phosphorylation of its cytoplasmic domain. Mutations in this gene cause Donnai-Barrow syndrome (DBS) and facio-oculoacoustico-renal syndrome (FOAR).[provided by RefSeq, Aug 2009]

ACMG classification

Verdict is Benign. Variant got -12 ACMG points.

• BP4: Computational evidence support a benign effect (BayesDel_noAF=-0.99).
• BA1: GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.908 is higher than 0.05.

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	MANE	Protein	UniProt
LRP2	NM_004525.3	c.9032+407T>G		intron_variant		ENST00000649046.1	NP_004516.2
LRP2	XM_011511183.4	c.9032+407T>G		intron_variant			XP_011509485.1
LRP2	XM_011511184.3	c.6743+407T>G		intron_variant			XP_011509486.1
LRP2	XM_047444340.1	c.8108+407T>G		intron_variant			XP_047300296.1

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	TSL	MANE	Protein	Appris	UniProt
LRP2	ENST00000649046.1	c.9032+407T>G		intron_variant			NM_004525.3	ENSP00000496870	P1

Frequencies

GnomAD3 genomes AF: 0.716 AC: 108879 AN: 151998 Hom.: 40543 Cov.: 32

Gnomad AFR AF: 0.915

Gnomad AMI AF: 0.754

Gnomad AMR AF: 0.532

Gnomad ASJ AF: 0.738

Gnomad EAS AF: 0.921

Gnomad SAS AF: 0.613

Gnomad FIN AF: 0.659

Gnomad MID AF: 0.712

Gnomad NFE AF: 0.636

Gnomad OTH AF: 0.705

We have no GnomAD4 exomes data on this position. Probably position not covered by the project.

GnomAD4 genome AF: 0.716 AC: 108974 AN: 152116 Hom.: 40589 Cov.: 32 AF XY: 0.712 AC XY: 52952 AN XY: 74354

Gnomad4 AFR AF: 0.916

Gnomad4 AMR AF: 0.531

Gnomad4 ASJ AF: 0.738

Gnomad4 EAS AF: 0.921

Gnomad4 SAS AF: 0.612

Gnomad4 FIN AF: 0.659

Gnomad4 NFE AF: 0.636

Gnomad4 OTH AF: 0.703

Alfa AF: 0.642 Hom.: 41325

Bravo AF: 0.719

Asia WGS AF: 0.736 AC: 2561 AN: 3478

ClinVar

Not reported in ClinVar

Computational scores

Source: dbNSFP v4.3

Name	Calibrated prediction	Score	Prediction
BayesDel_noAF	Benign	-0.99
CADD	Benign	0.87
DANN	Benign	0.35

Splicing

Name	Calibrated prediction	Score	Prediction
SpliceAI score (max)		0.0		Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Other links and lift over

dbSNP: rs7592152; hg19: chr2-170047935;